ENTERPRISE VASCULAR RECONSTRUCTION DEVICE AND DELIVERY SYSTEM
Report
- Report Number
- 1058196-2013-00056
- Event Type
- Death
- Date Received
- February 28, 2013
- Date of Event
- April 2, 2012
- Report Date
- February 7, 2013
- Manufacturer
- CORDIS NEUROVASCULAR, INC.
- Product Code
- NJE
- PMA / PMN Number
- H60001
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- FL, US
- Reporter Occupation
- HEALTH PROFESSIONAL
Narratives
ONE PATIENT DEATH WAS SECONDARY TO A PERIPROCEDURAL MYOCARDIAL INFARCTION DURING ELECTIVE COILING. THE MEAN AGE AT TIME OF ENTERPRISE STENT DEPLOYMENT WAS (B)(6) AND WOMEN REPRESENTED (B)(4) OF THE STUDY PATIENTS. THE MAJORITY OF TREATED ANEURYSMS WERE INTERNAL CAROTID ARTERY ANEURYSMS, WITH OPHTHALMIC SEGMENT ((B)(4)). MEAN ANEURYSM SIZE WAS 9.2 +/- 0.4 MM (MEDIAN, 7.0; RANGE, 1.5-35.0 MM). MEAN PARENT VESSEL SIZE WAS 3.3 +/- 0.1 MM (MEDIAN, 3.3 MM; RANGE, 1.5-5.7MM). THE AUTHORS CONCLUDED THAT ALTHOUGH THE STUDY IS LIMITED IN ITS RETROSPECTIVE NATURE THE ENTERPRISE STENT SYSTEM APPEARS TO BE AN EFFECTIVE, SAFE AND DURABLE TREATMENT FOR INTRACRANIAL ANEURYSMS WHEN USED IN CONJUNCTION WITH COILING. CONCLUSION: INFORMATION VIA A LITERATURE REVIEW WAS NOTED IN FARGEN, KYLE M., ET AL, "LONG-TERM RESULTS OF ENTERPRISE STENT-ASSISTED COILING OF CEREBRAL ANEURYSMS"; NEUROSURGERY VOL. 71, NO. 2, 8-2012. NINE CENTERS PROVIDED DE-IDENTIFIED DATA ON ALL CONSECUTIVE PATIENTS WHO UNDERWENT ENTERPRISE VRD DEPLOYMENT AS PART OF ANEURYSM TREATMENT PRIOR TO MAY 2009. (B)(4) PATIENTS WITH (B)(4) ANEURYSMS WERE INCLUDED IN THE STUDY. THERE WERE THREE DEATHS RELATED TO INTRACRANIAL HEMORRHAGE AND ONE DEATH DUE TO A PERIPROCEDURAL MYOCARDIAL INFARCTION. THERE WERE THREE INTRACRANIAL HEMORRHAGES WITHOUT DEATH OF THE PATIENT. THERE WERE (B)(4) REPORTED THROMBOEMBOLIC EVENTS, (B)(4) REPORTS OF INSTENT RESTENOSIS ((B)(4)), ATTEMPTED COILING WAS NOT ACCOMPLISHED SECONDARY TO STENT PROLAPSE IN ONE PATIENT, KINKED STENT IN ONE PATIENT AND REPEATED COIL PROLAPSE IN ONE PATIENT. THERE WAS ONE REPORT OF IATROGENIC CAROTID CAVERNOUS FISTULA. THERE IS NO UNIQUE IDENTIFYING PATIENT, TARGET SITE, EVENT DESCRIPTION, OR HOSPITAL INFORMATION. THE MEAN AGE AT TIME OF ENTERPRISE STENT DEPLOYMENT WAS (B)(4) AND WOMEN REPRESENTED (B)(4) OF THE STUDY PATIENTS. THE MAJORITY OF TREATED ANEURYSMS WERE INTERNAL CAROTID ARTERY ANEURYSMS, WITH OPHTHALMIC SEGMENT ((B)(4)). MEAN ANEURYSM SIZE WAS 9.2 +/- 0.4 MM (MEDIAN, 7.0; RANGE, 1.5-35.0 MM). MEAN PARENT VESSEL SIZE WAS 3.3 +/- 0.1 MM (MEDIAN, 3.3 MM; RANGE, 1.5-5.7MM). THE AUTHORS CONCLUDED THAT ALTHOUGH THE STUDY IS LIMITED IN ITS RETROSPECTIVE NATURE THE ENTERPRISE STENT SYSTEM APPEARS TO BE AN EFFECTIVE, SAFE AND DURABLE TREATMENT FOR INTRACRANIAL ANEURYSMS WHEN USED IN CONJUNCTION WITH COILING. THE DEVICES REMAIN IMPLANTED AND THE LOT NUMBERS ARE NOT KNOWN; THEREFORE A DEVICE HISTORY RECORD REVIEW CANNOT BE COMPLETED. ONE PATIENT DEATH WAS SECONDARY TO A PERIPROCEDURAL MYOCARDIAL INFARCTION THAT OCCURRED 3 DAYS AFTER ELECTIVE COILING OF AN UNRUPTURED 2.3CM POSTERIOR COMMUNICATING ARTERY ANEURYSM. AS OUTLINED IN THE INSTRUCTIONS FOR USE, MYOCARDIAL INFARCTION IS A KNOWN POTENTIAL ADVERSE EVENT THAT MAY BE ASSOCIATED WITH THE PROCEDURES IN WHICH THE ENTERPRISE IS USED IN. THERE IS NO INDICATION OF ANY DEVICE PERFORMANCE ISSUES IMPACTING THE EVENT AND IS LIKELY DUE TO THE PATIENT'S MEDICAL CONDITION AND COMORBIDITIES. THEREFORE, NO CORRECTIVE ACTIONS WILL BE TAKEN.
INFORMATION VIA A LITERATURE REVIEW WAS NOTED IN FARGEN, KYLE M., ET AL, "LONG-TERM RESULTS OF ENTERPRISE STENT-ASSISTED COILING OF CEREBRAL ANEURYSMS"; NEUROSURGERY VOL. 71, NO. 2, 8-2012. NINE CENTERS PROVIDED DE-IDENTIFIED DATA ON ALL CONSECUTIVE PATIENTS WHO UNDERWENT ENTERPRISE VRD DEPLOYMENT AS PART OF ANEURYSM TREATMENT PRIOR TO MAY 2009. (B)(4) PATIENTS WITH (B)(4) ANEURYSMS WERE INCLUDED IN THE STUDY. (
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 88176 | ENTERPRISE VASCULAR RECONSTRUCTION DEVICE AND DELIVERY SYSTEM | CNV ENTERPRISE SES (NJE) | NJE | CORDIS NEUROVASCULAR, INC. | NA | UNK |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | Death |